Snowball logo
logo
ALNY_logo

Alnylam Pharmaceuticals, Inc

$227.12+$3.17Β  (1.42%)
πŸ’‘ Click on a row in the table to make it appear on the graph
πŸ“Š Compare financials of multiple companies on the same chart
This feature is available with our premium plans. Upgrade to unlock the full potential of Snowball Analytics and be on top of your investments!
20212022202320242025TTM
Revenue
Total revenue
844.31,037.41,828.32,248.23,713.94,804.2
COGS
140.1168.8310.4323.4677.2974.3
Gross Profit
704.1868.61,517.91,924.93,036.83,829.8
Operating Expenses & Income
Operating Income
(708.7)(785.1)(282.2)(176.9)501.6999.8
Total Operating Expenses
1,412.81,653.71,800.12,101.82,535.22,830.1
R&D Expenses
792.28831,004.41,126.21,324.51,509
Selling General & Admin Expenses
620.6770.7795.6975.51,210.71,317.9
Earnings from Continuing Operations
Interest Expense
(143)(156)(121.2)(141.9)(252.6)(325.1)
Interest Income
1.57924.8195.56122111.5110.1
Income Tax Expense
0.684.1636.725(99.22)9.405(39.75)
Net Income
Net Income
(852.8)(1,131.2)(440.2)(278.2)313.7808
Supplemental
EBIT
(709.1)(971)(312.3)(235.5)575.81,095.9
EBITDA
(661.6)(926.6)(258.2)(178.8)631.41,150.4
In millions of USD, except % and values per 1 share